Summary:
A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Alogliptin plus Metformin, Alogliptin alone, or Metformin alone in subjects with Type II Diabetes.
Qualified Participants Must:
• Be 19 years of age or older
•
Have Type II Diabetes
•
Currently not taking any diabetic medication
Qualified Participants May Receive:
Study medication, physical exams, and lab work at no cost.